Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04593940 · ClinicalTrials.gov registry record · Phase 3
Immune Modulators for Treating COVID-19
A Phase 3 study, sponsored by Daniel Benjamin.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,971
- Enrollment target
NCT04593940 is a Phase 3 study that has completed, run by Daniel Benjamin. The registered enrollment target is 1,971 participants.
The verdict
NCT04593940, a Phase 3 study, has completed, sponsored by Daniel Benjamin.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,971 participants
- Enrollment target
Study Summary
ACTIV-1 IM is a master protocol designed to evaluate multiple investigational agents for the treatment of moderately or severely ill patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The research objectives are to evaluate each agent with respect to speed of recovery, mortality, illness severity, and hospital resource utilization. Each agent will be evaluated as add-on therapy to the standard of care (SoC) in use at the local clinics, including remdesivir (provided). The SoC may change during the course of the study based on other research findings. Comparisons of the agents among themselves is not a research objective. The study population corresponds to moderately and severely ill patients infected with the coronavirus disease 2019 (COVID-19) virus. Recruitment will target patients already hospitalized for treatment of COVID-19 infection as well as patients being treated for COVID-19 infection in Emergency Departments while waiting to be admitted to the hospital. Patients both in and out of the ICU are included in the study population.
Interventions
- DRUG Abatacept
- DRUG Infliximab
- DRUG Remdesivir
- DRUG cenicriviroc (closed to enrollment as of 3-Sep-2021)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,971 participants |
| Start Date | 2020-10-15 |
| Est. Completion | 2022-03-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04593940
The ClinicalTrials.gov registry entry for NCT04593940 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,971 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daniel Benjamin, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Abatacept is the first listed.
NCT04593940 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04593940 about?
NCT04593940 is a clinical study titled "Immune Modulators for Treating COVID-19". ACTIV-1 IM is a master protocol designed to evaluate multiple investigational agents for the treatment of moderately or severely ill patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The research objectives are to evaluate each agent with respect to speed of recove...
What is the current status of trial NCT04593940?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,971 participants. The study started on 2020-10-15. Estimated completion is 2022-03-05.
What interventions are being tested in trial NCT04593940?
The interventions under investigation include: Abatacept (DRUG), Infliximab (DRUG), Remdesivir (DRUG), cenicriviroc (closed to enrollment as of 3-Sep-2021) (DRUG).
Who is sponsoring clinical trial NCT04593940?
This trial is sponsored by Daniel Benjamin, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.